The starting material for virtually all pharmaceuticals and biologics is a synthetic or chemical. Human plasma-derived therapies are one of the few exceptions. A number of fragile proteins can be ...

CHARLESTON, S.C.--(BUSINESS WIRE)--Plasma Technologies LLC (PlasmaTech), a plasma biologics technology company, announced that its novel human plasma fractionation process has been shown to achieve a ...

The Insight Partners published latest research study on “Plasma Fractionation Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Application, End User, and Geography,” the ...

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced today that Grifols’ North Fractionation Facility in Clayton, N.C., was named the International Society for Pharmaceutical ...

Indonesia is set to host its first-ever plasma fractionation plant in Karawang, West Java, which is poised to become the ...

Plasma fractionation is the process of separating blood plasma into its individual components, such as clotting factors, immunoglobulins, and albumin, for therapeutic and medical use. The plasma ...

The plasma fractionation market is projected to reach US$ 40,731.98 million by 2028 from US$ 26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% during 2021-2028. According to the ...

The "Plasma Fractionation Market Industry Trends and Global Forecasts to 2035, by Type of Company, Scale of Operation, Type of Plasma-derived Therapeutic Products Manufactured, Therapeutic Areas of ...